AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2686494 — intervention group
Group type: COMPARATOR
Intervention: sodium nitroprusside in 0.5 micrograms.kg‐1.min‐1 increments
Number of subjects: 91
Study 31795966 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised breast cancer risk information (breast cancer prevention programme)
Number of subjects: 2094
Study 31795966 — intervention group
Group type: COMPARATOR
Intervention: Individualised breast cancer, cardiovascular disease and type 2 diabetes information (multiple disease prevention programme)
Number of subjects: 2094
Study 28159420 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge mechanical compression device (MCD) therapy
Number of subjects: 100
Study 28159420 — intervention group
Group type: COMPARATOR
Intervention: Inpatient mechanical compression device (MCD) therapy
Number of subjects: 100
Study 26159065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily plus cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 chemotherapy
Number of subjects: 265
Study 26159065 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily plus cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 chemotherapy
Number of subjects: 265
Study 26159065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 265
Study 26159065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 23732584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 180
Study 23732584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 21195076 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Behavioural Pain Scale (MBPS)
Number of subjects: 120
Study 21195076 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Infant Pain Scale (NIPS)
Number of subjects: 120
Study 21195076 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Legs Activity Cry Consolability Scale (FLACC)
Number of subjects: 120
Study 21195076 — intervention group
Group type: COMPARATOR
Intervention: PCV vaccine
Number of subjects: 120
Study 21195076 — intervention group
Group type: COMPARATOR
Intervention: DPTaP-Hib vaccine
Number of subjects: 120
Study 19943711 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac solution (40 drops four times daily)
Number of subjects: 0
Study 19943711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (50 drops three times daily)
Number of subjects: 0
Study 19943711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution
Number of subjects: 0
Study 17847938 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA therapy
Number of subjects: 60
Study 17847938 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid therapy
Number of subjects: 60
Study 15166685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam, 0.5-1.0 mg orally at bedtime for 7 days
Number of subjects: 18
Study 15166685 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone, 3.75-7.5 mg orally at bedtime for 7 days
Number of subjects: 18
Study 15166685 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone
Number of subjects: 18
Study 15166685 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 18
Study 11248744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg per day rhGH administered subcutaneously at 2200 h for four days
Number of subjects: 19
Study 9303394 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet cream
Number of subjects: 302
Study 9303394 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 302
Study 8322650 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute infusion of adenosine (140 micrograms/kg/min)
Number of subjects: 11
Study 8322650 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute infusion of adenosine (140 micrograms/kg/min)
Number of subjects: 11
Study 8322650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 3-minute and 6-minute infusions of adenosine
Number of subjects: 11
Study 3505706 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented group therapy (4 months)
Number of subjects: 17
Study 3505706 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 17
Study 30173337 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic contact lenses (TCL)
Number of subjects: 60
Study 30173337 — intervention group
Group type: COMPARATOR
Intervention: Tight bandage patching
Number of subjects: 60
Study 30173337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27053155 — intervention group
Group type: EXPERIMENTAL
Intervention: One Stretch exercise intervention with a 30-minute seminar and exercise manual
Number of subjects: 167
Study 27053155 — intervention group
Group type: EXPERIMENTAL
Intervention: One Stretch exercise intervention
Number of subjects: 167
Study 27053155 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the manual
Number of subjects: 167
Study 24886906 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surfactant treatment (Curosurf®)
Number of subjects: 2
Study 24886906 — intervention group
Group type: COMPARATOR
Intervention: Late surfactant treatment (Curosurf®)
Number of subjects: 2
Study 23078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking-plus-social marketing program
Number of subjects: 424
Study 23078486 — intervention group
Group type: COMPARATOR
Intervention: Walking-only program
Number of subjects: 424
Study 23078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led Pride Strides (social marketing component)
Number of subjects: 424
Study 23078486 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing approach
Number of subjects: 424
Study 20370916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 20370916 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 0
Study 20370916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18656509 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat leaves
Number of subjects: 6
Study 18656509 — intervention group
Group type: COMPARATOR
Intervention: Lettuce
Number of subjects: 6
Study 15752382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg as a sugar-coated tablet (SCT) after fasting
Number of subjects: 12
Study 15752382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg as a sugar-coated tablet (SCT) after food
Number of subjects: 12
Study 15752382 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg as a suspension after fasting
Number of subjects: 12
Study 11772328 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (elemental, semi‐elemental or polymeric diet) as the sole source of nutrition
Number of subjects: 0
Study 11772328 — intervention group
Group type: COMPARATOR
Intervention: Conventional corticosteroids
Number of subjects: 0
Study 11772328 — intervention group
Group type: COMPARATOR
Intervention: Ileal‐release preparation of budesonide
Number of subjects: 0
Study 11772328 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐Mercaptopurine (6‐MP) and its prodrug azathioprine
Number of subjects: 0
Study 10479170 — intervention group
Group type: EXPERIMENTAL
Intervention: PVL nadir below the limit of detection (LOD)
Number of subjects: 0
Study 10479170 — intervention group
Group type: EXPERIMENTAL
Intervention: PVL nadir detectable but not quantifiable
Number of subjects: 0
Study 10479170 — intervention group
Group type: EXPERIMENTAL
Intervention: PVL nadir below the LOD
Number of subjects: 0
Study 10479170 — intervention group
Group type: COMPARATOR
Intervention: PVL nadir >500 copies/mL
Number of subjects: 0
Study 8951265 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of elemental zinc daily)
Number of subjects: 93
Study 8951265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 93
Study 1618246 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 ml of 2% lignocaine with 1:80,000 adrenaline
Number of subjects: 16
Study 1618246 — intervention group
Group type: COMPARATOR
Intervention: 3% prilocaine with 0.03 IU.ml‐1 felypressin
Number of subjects: 16
Study 6367098 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg plus chlorthalidone 25 mg (Tenoretic)
Number of subjects: 0
Study 6367098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg plus hydrochlorothiazide 50 mg (Sotazide)
Number of subjects: 0
Study 30695290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (3, 6, or 9 mg/d)
Number of subjects: 200
Study 30695290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 28779419 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 2 mg/25 ml foam
Number of subjects: 126
Study 28779419 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam
Number of subjects: 126
Study 26872828 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 60
Study 26872828 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Muscle Vibration (LMV)
Number of subjects: 60
Study 26872828 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 24731008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fructose infusion
Number of subjects: 0
Study 24731008 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance)
Number of subjects: 0
Study 24731008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 0
Study 24731008 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemia
Number of subjects: 0
Study 22414844 — intervention group
Group type: COMPARATOR
Intervention: NaOCl irrigation without LAI (group N)
Number of subjects: 63
Study 22414844 — intervention group
Group type: COMPARATOR
Intervention: EDTA irrigation without LAI (group E)
Number of subjects: 63
Study 22414844 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI with NaOCl (group NL)
Number of subjects: 63
Study 22414844 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI with EDTA (group EL)
Number of subjects: 63
Study 19889010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional laser treatment (1,540-nm erbium glass laser)
Number of subjects: 12
Study 18418976 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Tiaojing Recipe (YSTJR) plus TP 20 mg three times a day
Number of subjects: 58
Study 18418976 — intervention group
Group type: COMPARATOR
Intervention: TP 20 mg three times a day (Control)
Number of subjects: 58
Study 15997346 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear catheter ablation
Number of subjects: 25
Study 12520149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 51
Study 12520149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 51
Study 10380745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (2.5 mg/ml) + epinephrine (5 microg/ml)
Number of subjects: 126
Study 10380745 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (5 microg/ml) + saline (9 mg/ml)
Number of subjects: 126
Study 10380745 — intervention group
Group type: COMPARATOR
Intervention: Saline (9 mg/ml) only
Number of subjects: 126
Study 8885909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute vasopressin solution (0.05 U/mL)
Number of subjects: 106
Study 8885909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 106
Study 1998274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 or 40 mg once or twice daily
Number of subjects: 8245
Study 1998274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study 6880927 — intervention group
Group type: EXPERIMENTAL
Intervention: Edible incentive
Number of subjects: 40
Study 6880927 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-edible incentive
Number of subjects: 40
Study 6880927 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for food vs non-food items
Number of subjects: 40
Study 31964335 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation of ferrous sulfate between 80 mg and 160 mg.
Number of subjects: 43
Study 31964335 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (observational study with no control group).
Number of subjects: 43
Study 31438346 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 0
Study 30337921 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-134a-beclomethasone dipropionate (HFA-BDP) metered-dose inhaler (MDI) ETN (n = 11)
Number of subjects: 23
Study 30337921 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-134a-beclomethasone dipropionate (HFA-BDP) metered-dose inhaler (MDI) ETN
Number of subjects: 23
Study 27494176 — intervention group
Group type: EXPERIMENTAL
Intervention: GTE confection (1 g of green tea extract)
Number of subjects: 15
Study 27494176 — intervention group
Group type: COMPARATOR
Intervention: Starch confection without GTE
Number of subjects: 15
Study 27494176 — intervention group
Group type: COMPARATOR
Intervention: Both confections (GTE and control)
Number of subjects: 15
Study 24864465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meldonium (idrinol) 1000 mg/day for 10-14 days
Number of subjects: 60
Study 24864465 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy of coronary heart disease (Control Group)
Number of subjects: 60
Study 22439290 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving Treatment-OcOccupational Therapy (PST-OT)
Number of subjects: 80
Study 19006186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral fetal nigral transplantation with 4 donors per side
Number of subjects: 34
Study 19006186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral fetal nigral transplantation with 1 donor per side
Number of subjects: 34
Study 19006186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19006186 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (on‐medication dyskinesia)
Number of subjects: 34
Study 17766719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 mmol/kg calcium gluconate intravenously for 3 hours
Number of subjects: 16
Study 17766719 — intervention group
Group type: COMPARATOR
Intervention: Calcium loading test in PHP patients
Number of subjects: 16
Study 16047182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 80
Study 16047182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12066244 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 g of oral barium tracer
Number of subjects: 119
Study 12066244 — intervention group
Group type: COMPARATOR
Intervention: 60 g of oral barium tracer
Number of subjects: 119
Study 12066244 — intervention group
Group type: COMPARATOR
Intervention: 150 g of oral barium tracer
Number of subjects: 119
Study 12066244 — intervention group
Group type: COMPARATOR
Intervention: Control group (no barium tracer)
Number of subjects: 119
Study 10434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 mg kg‐1
Number of subjects: 150
Study 10434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 150 mg kg‐1
Number of subjects: 150
Study 10434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 mg kg‐1 plus Dexamethasone 150 mg kg‐1
Number of subjects: 150
Study 11727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature buffered lidocaine
Number of subjects: 34
Study 11727685 — intervention group
Group type: COMPARATOR
Intervention: Warm plain lidocaine
Number of subjects: 34
Study 11727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm buffered lidocaine
Number of subjects: 34
Study 11727685 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature buffered lidocaine (Part II)
Number of subjects: 34
Study 1721881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 34
Study 1721881 — intervention group
Group type: COMPARATOR
Intervention: 3% polidocanol injection
Number of subjects: 34
Study 7045090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 33
Study 7045090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 33
Study 30862583 — intervention group
Group type: EXPERIMENTAL
Intervention: Template-guided CPS placement
Number of subjects: 4
Study 30862583 — intervention group
Group type: COMPARATOR
Intervention: Freehand CPS placement
Number of subjects: 4
Study 28936612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided tracheal intubation
Number of subjects: 266
Study 28936612 — intervention group
Group type: COMPARATOR
Intervention: Fiberscope-guided tracheal intubation
Number of subjects: 266
Study 27537530 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management with oral rivaroxaban 15 mg twice daily for 21 days followed by 20 mg once daily for 90 days
Number of subjects: 150
Study 27537530 — intervention group
Group type: COMPARATOR
Intervention: Standard care determined by the treating physician and based on local practices
Number of subjects: 150
Study 24240351 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg body weight of caffeine dissolved in 200 mL of water
Number of subjects: 41
Study 24240351 — intervention group
Group type: COMPARATOR
Intervention: 200 mL of water (placebo)
Number of subjects: 41
Study 22293063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (2 soy food servings/day)
Number of subjects: 82
Study 22293063 — intervention group
Group type: COMPARATOR
Intervention: Low-soy diet (<3 servings of soy/wk)
Number of subjects: 82
Study 19743737 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-mounted hydration systems (BM)
Number of subjects: 78
Study 19743737 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue (SI) canteens
Number of subjects: 78
Study 17234502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36) received weekly packets of fruits and vegetables, asked to consume >or=200 g of vegetables and two pieces of fruit daily for 1 month.
Number of subjects: 71
Study 17234502 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35) did not receive any intervention.
Number of subjects: 71
Study 15024533 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medicines use in the two least-educated groups
Number of subjects: 16690
Study 15024533 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medicines use in the two highest educated groups
Number of subjects: 16690
Study 15024533 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patterns of psychotropic medicine use
Number of subjects: 16690
Study 11779909 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese manual acupuncture (35 sessions over 10 weeks)
Number of subjects: 106
Study 11779909 — intervention group
Group type: COMPARATOR
Intervention: Standard modalities of treatment (physiotherapy, occupational and speech therapy, skilled medical and nursing care)
Number of subjects: 106
Study 9819000 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (4200 IU anti-Xa)
Number of subjects: 498
Study 9819000 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40mg, approximately 4000 IU anti-Xa)
Number of subjects: 498
Study 7652635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg IV)
Number of subjects: 20
Study 7652635 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (5 mg IV)
Number of subjects: 20
Study 2650942 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg per os
Number of subjects: 40
Study 2650942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 389513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 21
Study 389513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily + beta-blocker
Number of subjects: 21
Study 389513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30922146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 24 weeks
Number of subjects: 345
Study 30922146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 28182471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program using computer software (CogPack; Japanese version), administered twice a week for 12 weeks, including a weekly group session.
Number of subjects: 60
Study 28182471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Number of subjects: 60
Study 28182471 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 26376344 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda-1a (Lambda) with ribavirin
Number of subjects: 525
Study 24276103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous piracetam
Number of subjects: 200
Study 24276103 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dimenhydrinate
Number of subjects: 200
Study 21159432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment using the pain subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C‐30
Number of subjects: 718
Study 21159432 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 718
Study 19374740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 28
Study 19374740 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 28
Study 19374740 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 28
Study 19374740 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy individuals)
Number of subjects: 28
Study 19374740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 28
Study 19681256 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 52
Study 19681256 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.9% hydrogen peroxide paint‐on gel (Colgate Simply White)
Number of subjects: 52
Study 19681256 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (negative control)
Number of subjects: 52